Antimalarial drug resistance: surveillance and molecular methods for national malaria control programmes.
National malaria control programmes have the responsibility to develop a policy for malaria disease management based on a set of defined criteria as efficacy, side effects, costs and compliance. These will fluctuate over time and national guidelines will require periodic re-assessment and revision. Changing a drug policy is a major undertaking that can take several years before being fully operational. The standard methods on which a decision can be taken are the in vivo and the in vitro tests. The latter allow a quantitative measurement of the drug response and the assessment of several drugs at once. However, in terms of drug policy change its results might be difficult to interpret although they may be used as an early warning system for 2nd or 3rd line drugs. The new WHO 14-days in vivo test addresses mainly the problem of treatment failure and of haematological parameters changes in sick children. It gives valuable information on whether a drug still 'works'. None of these methods are well suited for large-scale studies. Molecular methods based on detection of mutations in parasite molecules targeted by antimalarial drugs could be attractive tools for surveillance. However, their relationship with in vivo test results needs to be established.
D'Alessandro
U
U
Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium. UDAlessandro@proto.itg.be
D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D004351:Drug Resistance; D017125:Genes, Protozoan / Q000235:genetics*; D006801:Humans; D008288:Malaria / Q000517:prevention & control*; D009313:National Health Programs; D010961:Plasmodium / Q000187:drug effects* / Q000235:genetics*; D011159:Population Surveillance
D000962:Antimalarials